Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Biomarkers of Risk of Parkinson Disease
NCT00775853 · View on ClinicalTrials.gov ↗
Study Summary
This study (https://pdrisk.ninds.nih.gov) will determine if people who have risk factors for Parkinson disease (PD) have biomarkers (objective ways to measure a disease process) that show that the disease process is actually going on, and if people who have abnormal biomarkers go on to develop PD during several years of follow-up. Biomarkers of Parkinson disease (PD) might identify people who are healthy now but may develop the disease later in life. Healthy volunteers and people who have certain risk factors for developing PD who are between 18 and 70 years of age may be eligible for this study. People with the following risk factors are included: * Family history of PD * Loss of sense of smell * Fall in blood pressure when standing up * REM behavior disorder (a type of sleep disturbance) Participants undergo the following tests and procedures: * Screening examination * Medical and neurological history and physical examination * Tests or rating scales for movement, sense of smell, mood, attention, fatigue, pain, and thinking. * Measurement of blood pressure and pulse rate while lying down and then standing up * Blood draw for genetic testing * Inpatient testing at the NIH Clinical Center for 2-3 days, including: * Measurements while blowing against a resistance * Measurements of blood pressure and pulse rate * Blood draws for levels of various chemicals * PET and MRI scanning * Lumbar puncture (spinal tap) * Electrocardiogram * Skin electrical conduction test (test of sweat production) * Skin and core temperature measurements * Transcranial ultrasound (sound-wave test of the head) * Follow-up testing (up to five visits in 18-month intervals) to repeat some of the tests listed above, excluding the genetic testing and spinal tap
Conditions Studied
Interventions
- DRUG 13N-Ammonia
- DRUG 6-[18F]Fluorodopamine
- DRUG 6-[18F]Fluorodopa
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center — Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2009-05-27 |
| Est. Completion | 2023-01-11 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00775853
The ClinicalTrials.gov registry entry for NCT00775853 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 339 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 3 interventions — of which 13N-Ammonia is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00775853 reports 1 study location spanning 1 distinct geographic area — top geographies include Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00775853 about?
NCT00775853 is a clinical study titled "Biomarkers of Risk of Parkinson Disease". This study (https://pdrisk.ninds.nih.gov) will determine if people who have risk factors for Parkinson disease (PD) have biomarkers (objective ways to measure a disease process) that show that the disease process is actually going on, and if people who have abnormal biomarkers go on to develop PD du...
What is the current status of trial NCT00775853?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2009-05-27. Estimated completion is 2023-01-11.
What conditions does trial NCT00775853 study?
This clinical trial studies the following conditions: Parkinson Disease, Pure Autonomic Failure, Autonomic Nervous System Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00775853?
The interventions under investigation include: 13N-Ammonia (DRUG), 6-[18F]Fluorodopamine (DRUG), 6-[18F]Fluorodopa (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00775853?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 339 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00775853 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.